

PATENT  
1110-0279P

## IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: Yoshiyuki UENO Conf.: 3959

Appl. No.: 09/700,338 Group: 1648

Filed: November 14, 2000 Examiner: U. Winkler

For: PREVENTIVES/REMEDIES FOR HEPATIC  
CIRRHOSISREPLY UNDER 37 C.F.R. §1.111Assistant Commissioner for Patents  
Washington, DC 20231

January 2, 2003

Sir:

In reply to the Office Action dated October 2, 2002, the following remarks are respectfully submitted in connection with the above-identified application.

REMARKSRejection under 35 U.S.C. §103

Claims 8 and 10-16 have been rejected under 35 U.S.C. §103 as being obvious over Kondo et al., in view of Harada et al. and Shirakawa et al.

Kondo et al. is asserted to teach that the administration of a soluble form of Fas to HbsAg transgenic mice prevented CTL-induced liver disease. Kondo et al. is further asserted to teach inhibition of disease progression with two animal models for hepatitis. Kondo et al. is asserted differ from the invention in

#8  
Recov  
5.9.3